New combo therapy aims to control returning lung cancer in targeted patients
NCT ID NCT07279935
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. About 100 participants in China will receive this combination and be monitored for how long the cancer stays stable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
NOT_YET_RECRUITINGBeijing, 100021, China
-
Research Site
RECRUITINGBeijing, 100044, China
-
Research Site
NOT_YET_RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
NOT_YET_RECRUITINGChengdu, 610041, China
-
Research Site
NOT_YET_RECRUITINGChongqing, 400016, China
-
Research Site
RECRUITINGFuzhou, 350001, China
-
Research Site
RECRUITINGFuzhou, 350005, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510080, China
-
Research Site
WITHDRAWNGuangzhou, 510100, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510289, China
-
Research Site
RECRUITINGHangzhou, 310020, China
-
Research Site
NOT_YET_RECRUITINGHefei, 230022, China
-
Research Site
WITHDRAWNHefei, 230031, China
-
Research Site
WITHDRAWNJinan, 250014, China
-
Research Site
RECRUITINGJinan, 250014, China
-
Research Site
WITHDRAWNKunming, 650118, China
-
Research Site
RECRUITINGNanchang, 330006, China
-
Research Site
NOT_YET_RECRUITINGNanchang, 330006, China
-
Research Site
WITHDRAWNNanjing, 2100008, China
-
Research Site
RECRUITINGNanjing, 210009, China
-
Research Site
RECRUITINGNingbo, 315010, China
-
Research Site
NOT_YET_RECRUITINGShanghai, 200030, China
-
Research Site
WITHDRAWNShanghai, 200120, China
-
Research Site
WITHDRAWNShanghai, 200433, China
-
Research Site
NOT_YET_RECRUITINGShenyang, 110004, China
-
Research Site
RECRUITINGShenyang, 110042, China
-
Research Site
RECRUITINGTianjin, 300060, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430022, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430030, China
-
Research Site
RECRUITINGXi'an, 710004, China
-
Research Site
WITHDRAWNXi'an, 710061, China
-
Research Site
RECRUITINGZhengzhou, 450008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?